New York, Jan 14, 2026, 12:55 (EST) — Regular session
- Edgewise Therapeutics shares rise about 11% in midday trade, outpacing biotech ETFs
- Company targets Q4 2026 top-line Becker muscular dystrophy data; aims for U.S. NDA in 1H 2027
- Investors next watch 1H 2026 readouts in hypertrophic cardiomyopathy and a Phase 1 heart-failure program
Shares of Edgewise Therapeutics Inc (EWTX.O) were up 10.6% at $27.59 by 12:55 p.m. EST on Wednesday after the drug developer laid out a 2026 schedule for clinical readouts and trial starts across its muscle-disease and cardiac pipeline.
The move matters because Edgewise is still pre-commercial, and its valuation hangs on when — and how cleanly — the next sets of data arrive. In biotech, dates can trade almost like earnings.
Edgewise used the J.P. Morgan Healthcare Conference this week to tighten up its roadmap, giving investors a clearer sequence of catalysts from the first half of 2026 through next year. That kind of calendar can pull in short-term money fast, and it can leave just as quickly.
On Tuesday the company said it expects “top-line” results — an early headline look at trial data — from the GRAND CANYON pivotal cohort of sevasemten in Becker muscular dystrophy in the fourth quarter of 2026, and is preparing a U.S. New Drug Application in the first half of 2027. Chief executive Kevin Koch said 2025 delivered “disciplined execution” as the company heads into what it described as multiple near-term catalysts. PR Newswire
In its conference deck, Edgewise said there are no FDA-approved therapies for Becker, a rare genetic disease that weakens muscles over time. The presentation also said the company ended 2025 with more than $500 million in cash and runway through 2028, and described sevasemten as an oral, first-in-class fast skeletal myosin inhibitor.
For its heart program, Edgewise expects 12-week data in the first half of 2026 from CIRRUS-HCM, a Phase 2 study of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy, a condition marked by thickened heart muscle. It also expects Phase 1 dose-escalation data for EDG-15400 in healthy adults in the first half of 2026 and plans a Phase 2 study in heart failure with preserved ejection fraction, or HFpEF.
Competition is no longer theoretical in HCM. Cytokinetics won U.S. approval in December for Myqorzo (aficamten), a cardiac myosin inhibitor, joining Bristol Myers Squibb’s Camzyos for adults with symptomatic obstructive HCM.
Edgewise’s move on Wednesday also outpaced broader biotech benchmarks; the SPDR S&P Biotech ETF was up about 1.2% in midday trade, while the iShares Nasdaq Biotechnology ETF was little changed. About 1.0 million Edgewise shares had traded so far, after swinging between $24.74 and $27.64.
But the upside case still hinges on execution and trial risk. Edgewise has no approved products, and it cautioned that interim and top-line results can change as additional patient data is analyzed, while later-stage trials can miss earlier signals.
What comes next is nearer-term. Investors will watch for CIRRUS-HCM 12-week results and EDG-15400 Phase 1 data in the first half of 2026, before the longer wait for GRAND CANYON top-line Becker data in the fourth quarter of 2026.
